ARTICLE | Finance

Regulatory Milestones

Highlights of weekly biotech stock moves

July 26, 2010 7:00 AM UTC

Abraxis BioScience Inc. (NASDAQ:ABII) gained $0.05 to $74.42 last week after Japan's Ministry of Health, Labor and Welfare (MHLW) approved Abraxane nab-paclitaxel to treat breast cancer. Taiho Pharmaceutical Co. Ltd., a subsidiary of Otsuka Holdings Co. Ltd. (Tokyo:4768), has Japanese rights to the albumin stabilized nanoparticle formulation of paclitaxel.

Celgene Corp. (NASDAQ:CELG), which is in the process of acquiring Abraxis, was up $0.71 to $52.75 on the week...